Company

Cerevel Therapeutics Holdings, Inc.

Headquarters: Cambridge, MA, United States

Founded: 1996

Employees: 200

CEO: Dr. N. Anthony Coles Jr., M.P.H.

NASDAQ: CERE -0.53%

Market Cap

$7.63 Billion

USD as of Jan. 1, 2024

history Market Cap History

Cerevel Therapeutics Holdings, Inc. market capitalization over time

Evolution of Cerevel Therapeutics Holdings, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Cerevel Therapeutics Holdings, Inc.

Detailed Description

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

Cerevel Therapeutics Holdings, Inc. has the following listings and related stock indices.


Stock: NASDAQ: CERE wb_incandescent

Product & Services

Seeds of energy crops

Key People

Richard Hamilton (President and CEO)

Details

Headquarters:

222 Jacobs Street

Suite 200

Cambridge, MA 02141

United States

Phone: 844 304 2048